선천성 고혈압 쥐에서 Imatinib Mesylate가 심근 섬유화에 미치는 영향
Imatinib Mesylate Attenuates Cardiac Fibrosis in Spontaneously Hypertensive Rats
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Hypertensive myocardial fibrosis promotes abnormalities of cardiac function that may adversely affect the clinical outcome of hypertensive patients. Imatinib mesylate blocks receptor tyrosine kinase and is clinically used to treat leukemia. Platelet-derived growth factor (PDGF) is a downstream target of receptor tyrosine kinases. Cardiac fibroblasts can be activated by PDGF. Thus we evaluated whether imatinib attenuate myocardial fibrosis and prevents diastolic dysfunction in spontaneously hypertensive rats (SHR). Methods: 8 weeks old male SHRs were subjected to treatment with 8 weeks of low dose imatinib (SHR-10; 10 mg/kg), high dose imatinib (SHR-30; 30 mg/kg) or saline (SHR-C; n = 6 in each group). At the age of 16 weeks,all rats underwent hemodynamic studies and Doppler echocardiography, and were sacrificed. Their hearts were extracted for histopathological, immunoblotting and quantitative reverse transcriptase-polymerase chain reaction analyses. Results: While imatinib did not affect blood pressure (BP), it markedly reduced perivascular and interstitial fibrosis in the hearts of SHR. Echocardigram showed that high-dose imatinib significantly reduced left ventricular (LV) wall thickness (septal/posterior wall;SHR-C vs. SHR-30: 18 ± 2/19 ± 2 mm vs. 15 ± 1/14 ± 1 mm; p < 0.05) and improved the parameters of LV diastolic function such as E/A ratio (SHR-C vs. SHR-30: 1.60 ± 0.10 vs. 1.86 ± 0.20; p < 0.05). Imatinib also significantly reduced mRNA expression of collagen III and PDGF β-receptor tyrosine phosphorylation in the hearts of SHR. Conclusions: These results suggest that imatinib, especially high dose, could attenuate myocardial fibrosis and prevent LV diastolic dysfunction in hypertensive rat model by decreased activity of PDGF. Imatinib may provide a potential therapeutic approach for hypertensive heart disease.
Abstract
Background: Hypertensive myocardial fibrosis promotes abnormalities of cardiac function that may adversely affect the clinical outcome of hypertensive patients. Imatinib mesylate blocks receptor tyrosine kinase and is clinically used to treat leukemia. Platelet-derived growth factor (PDGF) is a downstream target of receptor tyrosine kinases. Cardiac fibroblasts can be activated by PDGF. Thus we evaluated whether imatinib attenuate myocardial fibrosis and prevents diastolic dysfunction in spontaneously hypertensive rats (SHR). Methods: 8 weeks old male SHRs were subjected to treatment with 8 weeks of low dose imatinib (SHR-10; 10 mg/kg), high dose imatinib (SHR-30; 30 mg/kg) or saline (SHR-C; n = 6 in each group). At the age of 16 weeks,all rats underwent hemodynamic studies and Doppler echocardiography, and were sacrificed. Their hearts were extracted for histopathological, immunoblotting and quantitative reverse transcriptase-polymerase chain reaction analyses. Results: While imatinib did not affect blood pressure (BP), it markedly reduced perivascular and interstitial fibrosis in the hearts of SHR. Echocardigram showed that high-dose imatinib significantly reduced left ventricular (LV) wall thickness (septal/posterior wall;SHR-C vs. SHR-30: 18 ± 2/19 ± 2 mm vs. 15 ± 1/14 ± 1 mm; p < 0.05) and improved the parameters of LV diastolic function such as E/A ratio (SHR-C vs. SHR-30: 1.60 ± 0.10 vs. 1.86 ± 0.20; p < 0.05). Imatinib also significantly reduced mRNA expression of collagen III and PDGF β-receptor tyrosine phosphorylation in the hearts of SHR. Conclusions: These results suggest that imatinib, especially high dose, could attenuate myocardial fibrosis and prevent LV diastolic dysfunction in hypertensive rat model by decreased activity of PDGF. Imatinib may provide a potential therapeutic approach for hypertensive heart disease.
참고문헌 (36)
- Ruy KH, "Clinical characterisrics and prognositic factors of patients with congestive heart failure in Korea (epidemiology of congestive heart failure in Korea)", Journal of the Korean Society of Hypertension, 8, pp.38~47 (2002)
- Kim TS, "From hypertension to heart failure", Journal of the Korean Society of Hypertension, 15, pp.1~11 (2009)
- Conrad CH, "Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat", Circulation, 91, pp.161~170 (1995)
- Creemers EE, "Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart", Cardiovascular Research, 89, pp.265~272 (2011)
- Rosenkranz S, "Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1)", American Journal of Physiology - Heart and Circulatory Physiology, 283, pp.1253~1262 (2002)
- Isoda K, "Myocardial hypertrophy in transgenic mice overexpressing human interleukin 1alpha", Journal of Cardiac Failure, 7, pp.355~364 (2001)
- Bryant D, "Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha", Circulation, 98, pp.1375~1381 (1998)
- Ponten A, "Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy", American Journal of Pathology, 163, pp.673~682 (2003)
- din CH, "Mechanism of action and in vivo role of platelet-derived growth factor", Physiological Reviews, 79, pp.1283~1316 (1999)
- Uutela M, "PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis", Blood, 104, pp.3198~3204 (2004)
- Fredriksson L, "The PDGF family: four gene products form five dimeric isoforms", Cytokine & Growth Factor Reviews, 15, pp.197~204 (2004)
- Savage DG, "Imatinib mesylate--a new oral targeted therapy", The New England Journal of Medicine, 346, pp.683~693 (2002)
- Bing OH, "The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure", Journal of Molecular and Cellular Cardiology, 27, pp.383~369 (1995)
- Cingolani OH, "Carretero OA. Reduction of cardiac fibrosis decreases systolic performance without affecting diastolic function in hypertensive rats", Hypertension, 43, pp.1067~1073 (2004)
- Daniels CE, "Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis", Journal of Clinical Investigation, 114, pp.1308~1316 (2004)
- Aono Y, "Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice", American Journal of Respiratory and Critical Care Medicine, 171, pp.1279~1285 (2005)
- Abdollahi A, "Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis", Journal of Experimental Medicine, 201, pp.925~935 (2005)
- Distler JH, "Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis", Arthritis & Rheumatism, 56, pp.311~322 (2007)
- Soria A, "The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study", Dermatology, 216, pp.109~117 (2008)
- Wang S, "Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo", FASEB Journal, 19, pp.1~11 (2005)
- Leipner C, "Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis", Cardiovascular Research, 79, pp.118~126 (2008)
- Schellings MW, "Imatinib attenuates end-organ damage in hypertensive homozygous TGR (mRen2)27 rats", Hypertension, 47, pp.467~474 (2006)
- Berk BC, "ECM remodeling in hypertensive heart disease", Journal of Clinical Investigation, 117, pp.568~575 (2007)
- Bhattacharyya S, "A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate", Oncogene, 28, pp.1285~1297 (2009)
- Tuuminen R, "PDGF-A, -C, and -D but not PDGF-B increase TGF-beta1 and chronic rejection in rat cardiac allografts", Arteriosclerosis, Thrombosis, and Vascular Biology, 29, pp.691~698 (2009)
- Oudit GY, "Cardiac regulation by phosphoinositide 3-kinases and PTEN", Cardiovascular Research, 82, pp.250~260 (2009)
- Shimizu T, "Platelet-derived growth factor induces cellular growth in cultured chick ventricular myocytes", Cardiovascular Research, 41, pp.641~653 (1999)
- Liu J, "Growth-promoting effect of platelet-derived growth factor on rat cardiac myocytes", 127, pp.11~18 (2005)
- Kagiyama S, "Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy", Hypertension, 41, pp.824~829 (2003)
- Smith NJ, "Hijacking epidermal growth factor receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy", Cellular and Molecular Life Sciences, 61, pp.2695~2703 (2004)
- Kerkela R, "Cardiotoxicity of the cancer therapeutic agent imatinib mesylate", Nature Medicine, 12, pp.908~916 (2006)
- Force T, "Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition", Nature Reviews Cancer, 6, pp.332~344 (2007)
- Druker BJ, "Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia", The New England Journal of Medicine, 355, pp.2408~2417 (2006)
- Hochhaus A, "Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment", Blood, 111, pp.1039~1043 (2008)
- Perik PJ, "Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity", Annals of Oncology, 19, pp.359~361 (2008)
- Ribeiro AL, "An evaluation of the cardiotoxicity of imatinib mesylate", Leukemia Research, 32, pp.1809~1814 (2008)